The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.
Maxime BoussageonAurélie SwalduzMaurice PérolPublished in: Expert review of anticancer therapy (2021)
RELAY confirmed the clinical relevance of combining EGFR and VEGF(R)-targeting therapies, previously investigated in smaller phase 2-3 trials of erlotinib and bevacizumab. However, the meaningful PFS benefit observed in the ramucirumab + erlotinib arm is counterbalanced by the toxicity profile of ramucirumab and the need for bimonthly infusions. Pending OS results are, therefore, critical to assess the real benefit from this combination, especially as first-line osimertinib has improved survival in EGFR-mutant NSCLC patients and will probably remain the pivotal EGFR-TKI in this setting. However, its heterogeneous efficacy across subgroups paves the way for osimertinib-based combinations, which are being investigated in ongoing trials.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- small cell lung cancer
- tyrosine kinase
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- peritoneal dialysis
- atomic force microscopy
- prognostic factors
- cancer therapy
- wild type
- drug delivery
- high speed
- free survival